提吉特
CD8型
细胞毒性T细胞
效应器
T细胞
免疫系统
癌症研究
细胞生物学
免疫学
生物
受体
体外
生物化学
作者
Robert J. Johnston,Laëtitia Comps‐Agrar,Jason A. Hackney,Xin Yu,Mahrukh A. Huseni,Yagai Yang,Summer Park,Vincent Javinal,Henry H. Chiu,Bryan A. Irving,Dan Eaton,Jane L. Grogan
出处
期刊:Cancer Cell
[Cell Press]
日期:2014-11-26
卷期号:26 (6): 923-937
被引量:1256
标识
DOI:10.1016/j.ccell.2014.10.018
摘要
Tumors constitute highly suppressive microenvironments in which infiltrating T cells are “exhausted” by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor and other CD8+ T cell-dependent chronic immune responses. TIGIT is highly expressed on human and murine tumor-infiltrating T cells, and, in models of both cancer and chronic viral infection, antibody coblockade of TIGIT and PD-L1 synergistically and specifically enhanced CD8+ T cell effector function, resulting in significant tumor and viral clearance, respectively. This effect was abrogated by blockade of TIGIT’s complementary costimulatory receptor, CD226, whose dimerization is disrupted upon direct interaction with TIGIT in cis. These results define a key role for TIGIT in inhibiting chronic CD8+ T cell-dependent responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI